Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. | Front Immunol | 2023 | 38239352 | PubTator, text mining | PubMed |
| Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. | Cancers (Basel) | 2023 | 38201551 | PubTator, text mining | PubMed |
| Promising and Minimally Invasive Biomarkers: Targeting Melanoma. | Cells | 2023 | 38201222 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors in sarcomas: a systematic review. | Immunooncol Technol | 2023 | 38192615 | PubTator, text mining | PubMed |
| ACE configurator for ELISpot: optimizing combinatorial design of pooled ELISpot assays with an epitope similarity model. | Brief Bioinform | 2023 | 38180831 | PubTator, text mining | PubMed |
| Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma. | Aging (Albany NY) | 2023 | 38180104 | PubTator, text mining | PubMed |
| Emerging Applications of Liquid Biopsies in Ovarian Cancer. | Cureus | 2023 | 38174205 | PubTator, text mining | PubMed |
| Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. | Front Immunol | 2023 | 38169820 | PubTator, text mining | PubMed |
| PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma. | Invest Ophthalmol Vis Sci | 2023 | 38149971 | PubTator, text mining | PubMed |
| A pyroptosis-related signature in colorectal cancer: exploring its prognostic value and immunological characteristics. | PeerJ | 2023 | 38144182 | PubTator, text mining | PubMed |
| The Limitations of Current T Cell-Driven Anticancer Immunotherapies Can Be Overcome with an Original Extracellular-Vesicle-Based Vaccine Strategy. | Vaccines (Basel) | 2023 | 38140250 | PubTator, text mining | PubMed |
| Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes. | Pharmaceutics | 2023 | 38140114 | PubTator, text mining | PubMed |
| How the Intrinsically Disordered N-Terminus of Cancer/Testis Antigen MAGEA10 Is Responsible for Its Expression, Nuclear Localisation and Aberrant Migration. | Biomolecules | 2023 | 38136576 | PubTator, text mining | PubMed |
| Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. | Cancers (Basel) | 2023 | 38136402 | PubTator, text mining | PubMed |
Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis. | J Immunother Cancer | 2023 | 38135347 | PubTator, text mining | PubMed |
| Autologous engineered T cell receptor therapy in advanced cancer. | Hum Vaccin Immunother | 2023 | 38114231 | PubTator, text mining | PubMed |
| Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23. | Hum Vaccin Immunother | 2023 | 38100550 | PubTator, text mining | PubMed |
| Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy. | Front Immunol | 2023 | 38098487 | PubTator, text mining | PubMed |
| DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies. | Front Immunol | 2023 | 38090585 | PubTator, text mining | PubMed |
| Therapeutic cancer vaccines: advancements, challenges, and prospects. | Signal Transduct Target Ther | 2023 | 38086815 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=6